lin28a Antibody

What is Lin28A and why is it a significant research target?

Lin28A is a highly conserved RNA-binding protein that plays crucial roles in developmental timing, pluripotency, and metabolism. It functions as a "translational enhancer" that drives specific mRNAs to polysomes and increases protein synthesis efficiency . Lin28A is particularly important in stem cell biology as one of the four key human factors (along with OCT4, SOX2, and NANOG) used to reprogram human fibroblasts to induced pluripotent stem cells .

Lin28A's significance extends to its role as a suppressor of microRNA biogenesis, particularly of the let-7 family, which has implications in oncogene repression . Additionally, Lin28A serves as a marker of spermatogonial stem cells and promotes their proliferation capacity, making it valuable for reproductive biology research .

How do I select the most appropriate Lin28A antibody for my specific experimental application?

Selection of an appropriate Lin28A antibody should be based on multiple factors including:

• Experimental application compatibility: Different antibodies demonstrate varied performance across applications. For instance, antibody #16177-1-AP shows the following application-specific dilution recommendations:

Always verify that your chosen antibody has been validated for your specific application .

• Species reactivity: Ensure the antibody recognizes Lin28A in your species of interest. For example, antibody #3978 shows reactivity with human and mouse samples , while others may have broader cross-reactivity with rat samples as well .

• Clonality: Consider whether a monoclonal or polyclonal antibody better suits your needs. Monoclonal antibodies offer higher specificity for a single epitope, while polyclonal antibodies can provide stronger signal by recognizing multiple epitopes but may show more background .

• Validation data: Review published literature citing the antibody and manufacturer's validation data, including positive controls used (e.g., hESC cells, NCCIT cells for Lin28A) .

What positive and negative controls should be included when validating a Lin28A antibody?

Proper validation requires thoughtfully selected controls:

Positive controls should include tissue or cell types known to express Lin28A at detectable levels:

• Human embryonic stem cells (hESCs)

• NCCIT cells (pluripotent embryonal carcinoma cells)

• Human testis tissue

• Human ovary tissue

• Human brain tissue

• NTera-2 human testicular embryonic carcinoma cell line

• JAR human choriocarcinoma cell line

Negative controls should include:

• Differentiated cells known to downregulate Lin28A

• Lin28A knockout cell lines (generated via CRISPR-Cas9)

• Primary antibody omission controls

• Isotype controls matching the primary antibody's host species

For recombinant expression systems, comparing Lin28A-transfected cells with empty vector controls provides an excellent validation method, as demonstrated in studies where Lin28A was overexpressed in GmGSCs-I-SB cells .

What are the optimal protocols for using Lin28A antibodies in Western blot applications?

For optimal Western blot results with Lin28A antibodies:

• Sample preparation:

  • Extract proteins using RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if investigating post-translational modifications

  • Sonication may improve yield as Lin28A can associate with RNA

• Loading and separation:

  • Load 20-40 μg of total protein per lane

  • Use 12-15% SDS-PAGE gels for optimal resolution around 28-30 kDa (observed molecular weight of Lin28A)

• Transfer and blocking:

  • Transfer to PVDF membrane (shown effective in published protocols)

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Antibody incubation:

  • Primary antibody dilution: 1:200-1:1000 (antibody-dependent, see table in question 1.2)

  • Incubate overnight at 4°C

  • Secondary antibody: Follow manufacturer recommendations (typically 1:5000-1:10000)

• Detection:

  • Enhanced chemiluminescence (ECL) systems work well for Lin28A detection

  • Expected band size: The calculated molecular weight of Lin28A is 23 kDa, but it commonly appears at 28-30 kDa on Western blots due to post-translational modifications

Publications consistently report strong and specific detection of Lin28A using these parameters, though optimization may be required for specific sample types .

What are the critical considerations for immunohistochemistry/immunofluorescence applications with Lin28A antibodies?

For successful IHC/IF with Lin28A antibodies:

• Sample fixation and preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues: 10% neutral buffered formalin fixation

  • Frozen sections: 4% paraformaldehyde fixation for 10-15 minutes is typically sufficient

  • Cell cultures: 4% paraformaldehyde for 15 minutes at room temperature

• Antigen retrieval is critical:

  • Recommended: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Heat-mediated retrieval (pressure cooker or microwave) typically yields better results than enzymatic methods

• Blocking and permeabilization:

  • Block with 5-10% normal serum from the species of secondary antibody

  • For cellular immunofluorescence: Include 0.1-0.3% Triton X-100 for permeabilization

• Antibody dilution and incubation:

  • IHC applications: 1:20-1:200 dilution range

  • IF applications: Typically 1:100-1:800

  • Incubate overnight at 4°C for optimal results

• Controls and counterstaining:

  • Include positive control tissues (testis, small intestine, ovary)

  • Nuclear counterstain: DAPI works well for immunofluorescence

  • For IHC: Hematoxylin counterstain allows visualization of tissue architecture

Lin28A primarily shows cytoplasmic localization with occasional nuclear presence, which is important to consider when evaluating staining patterns .

How can Lin28A antibodies be used to investigate Lin28A-let-7 pathway interactions?

The Lin28A-let-7 regulatory axis can be studied using several antibody-based approaches:

• RNA immunoprecipitation (RIP):

  • Use Lin28A antibodies to pulldown Lin28A-bound RNA complexes

  • Follow with qRT-PCR to quantify associated pre-let-7 miRNAs

  • This reveals direct RNA-protein interactions in your cell/tissue of interest

• Co-immunoprecipitation (Co-IP):

  • Precipitate Lin28A using specific antibodies

  • Analyze associated proteins involved in let-7 processing (such as TUT4/7)

  • Western blot analysis of precipitates can reveal protein interaction networks

• Combined approaches:

  • Chromatin immunoprecipitation sequencing (ChIP-seq) combined with RNA-seq after Lin28A manipulation

  • Comparison of let-7 family expression levels in control vs. Lin28A-overexpressing or knockdown samples

• Methodological considerations:

  • Include RNase inhibitors in all buffers when studying RNA-protein interactions

  • Cross-linking prior to immunoprecipitation may better preserve transient interactions

  • Use antibodies validated specifically for immunoprecipitation

The research has shown that Lin28A binds to pre-miRNAs by recognizing a 5'-GGAG-3' motif in the terminal loop, then recruits TUT4 and TUT7 uridylyltransferases . Using these antibody-based techniques allows for detailed investigation of this mechanistic pathway.

Why might Western blot analysis with Lin28A antibodies show multiple bands, and how should this be interpreted?

Multiple bands in Lin28A Western blots may occur for several legitimate reasons:

• Post-translational modifications:

  • Lin28A undergoes phosphorylation and potentially ubiquitination

  • The calculated molecular weight is 23 kDa, but the observed molecular weight is typically 28-30 kDa

  • Different phosphorylation states may appear as closely spaced bands

• Potential isoforms or degradation products:

  • Proteolytic cleavage during sample preparation

  • Alternative splice variants (though less common for Lin28A)

• Cross-reactivity considerations:

  • Some antibodies may cross-react with the paralog Lin28B

  • Verify specificity using Lin28A knockout/knockdown controls

Interpretation guidance:

• The primary Lin28A band should be observed at approximately 28 kDa

• Include positive control lysates (e.g., hESC cells, NCCIT cells) to identify the correct band

• If investigating novel tissue/cell types, validate using orthogonal methods (e.g., mass spectrometry or RNA expression data)

• Customer reviews have noted strong, specific signals at the 25-37 kDa range with 1:1000 dilution

How should discrepancies between Lin28A antibody staining patterns and expected expression patterns be resolved?

When Lin28A antibody staining patterns don't match expectations:

• Verify antibody specificity:

  • Test multiple Lin28A antibodies targeting different epitopes

  • Include appropriate positive controls (e.g., human embryonic stem cells, testis tissue)

  • Perform parallel knockdown/knockout experiments to confirm specificity

• Consider technical factors:

  • Optimize antigen retrieval methods (test both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Adjust antibody concentration and incubation conditions

  • Evaluate fixation protocols (overfixation can mask epitopes)

• Validate with orthogonal methods:

  • Compare protein expression (antibody-based) with mRNA expression (RT-PCR or RNA-seq)

  • Use in situ hybridization to visualize Lin28A transcript localization

  • Consider mass spectrometry-based protein identification

• Biological considerations:

  • Lin28A expression is developmentally regulated and tissue-specific

  • Expression patterns may vary with physiological or pathological states

  • Consider whether experimental conditions may have altered Lin28A expression

Published studies have verified Lin28A expression in specific tissues including small intestine, ovary, heart, testis, spleen, lung, and brain tissues , which can serve as reference points for expected expression patterns.

What factors might lead to inconsistent results when using Lin28A antibodies across different experimental systems?

Several factors can contribute to inconsistency across experimental systems:

• Antibody-related factors:

  • Lot-to-lot variability (particularly with polyclonal antibodies)

  • Antibody degradation due to improper storage or repeated freeze-thaw cycles

  • Different epitope accessibility across various applications

  • Non-specific binding in certain buffer conditions

• Sample preparation variables:

  • Fixation methods and duration affecting epitope presentation

  • Protein extraction protocols influencing protein conformation

  • Sample buffer composition affecting antibody binding

• Biological variables:

  • Cell/tissue-specific post-translational modifications of Lin28A

  • Differential expression of Lin28A binding partners that may mask epitopes

  • Variable expression levels requiring different detection sensitivities

• Technical recommendations:

  • Standardize protocols across experiments

  • Document antibody source, catalog number, lot number, and dilution

  • Test each new antibody lot against a reference sample

  • Consider creating a standard positive control that can be included in each experiment

  • Store antibodies according to manufacturer recommendations (e.g., at -20°C with glycerol)

How can Lin28A antibodies be utilized to investigate the role of Lin28A in cellular reprogramming and pluripotency?

Lin28A antibodies enable sophisticated investigations into reprogramming and pluripotency:

• Monitoring reprogramming efficiency:

  • Track Lin28A expression during the reprogramming process using immunofluorescence or Western blotting

  • Correlate Lin28A levels with pluripotency marker expression (OCT4, SOX2, NANOG)

  • Quantify nuclear vs. cytoplasmic distribution as reprogramming progresses

• Mechanistic investigations:

  • Combine with RNA immunoprecipitation to identify Lin28A-bound transcripts during reprogramming

  • Use ChIP-seq approaches to map Lin28A interactions with chromatin-associated factors

  • Investigate interactions with other pluripotency factors through co-immunoprecipitation

• Functional genomics approaches:

  • Apply Lin28A antibodies for CUT&RUN or CUT&Tag assays to map genomic associations with high resolution

  • Use for Proximity Ligation Assay (PLA) to detect interactions with other reprogramming factors

  • Develop FACS-based protocols to isolate Lin28A-positive cell populations during reprogramming

• Methodological insights:

  • Research shows Lin28A maintains self-renewal by upregulating expression of pluripotency factors OCT4, SOX2, GFRA1, PLZF, and ETV5

  • Lin28A can activate AKT, ERK, and mTOR signaling pathways to promote proliferation and maintain self-renewal

  • Overexpression of Lin28A enhances reprogramming efficiency, providing a useful experimental system for antibody-based studies

What are the optimal methods for combining Lin28A antibodies with functional assays to study its role in cancer and development?

Integrating Lin28A antibodies with functional assays provides powerful insights:

• Cancer research applications:

  • Use antibodies to sort Lin28A-positive vs. negative populations from patient-derived xenografts

  • Apply immunohistochemistry to correlate Lin28A expression with clinical outcomes

  • Combine with cell proliferation assays to assess functional consequences of Lin28A expression

  • Research shows Lin28A is involved in promoting de novo fatty acid synthesis in cancer progression

• Developmental biology applications:

  • Track Lin28A expression during tissue differentiation using immunofluorescence

  • Combine with lineage tracing to follow the fate of Lin28A-expressing cells

  • Use for organoid immunostaining to assess developmental patterning

• Integrated approaches:

  • CRISPR-mediated tagging of endogenous Lin28A followed by antibody-based pulldown

  • Tissue-specific conditional knockout models validated with antibody staining

  • Single-cell approaches combining antibody-based protein detection with transcriptomics

• Methodological considerations:

  • When assessing cancer stem cell-like signatures, combine Lin28A antibodies with other stem cell markers

  • For developmental studies, temporal resolution is critical - consider multiple timepoints

  • Validated positive controls include human testis tissue (showing strong Lin28A expression) and embryonic stem cells

How can Lin28A antibodies be employed to investigate post-translational modifications and protein interactions of Lin28A?

Advanced techniques for investigating Lin28A modifications and interactions:

• Post-translational modification (PTM) analysis:

  • Use phospho-specific Lin28A antibodies when available

  • Employ immunoprecipitation with Lin28A antibodies followed by mass spectrometry

  • Combine with lambda phosphatase treatment to confirm phosphorylation events

  • Sequential immunoprecipitation can isolate specific modified forms of Lin28A

• Protein interaction studies:

  • Co-immunoprecipitation using Lin28A antibodies to identify binding partners

  • Proximity labeling approaches (BioID or APEX) combined with Lin28A antibodies

  • Förster Resonance Energy Transfer (FRET) microscopy using labeled antibodies

  • Protein complementation assays to validate direct interactions

• Technical considerations:

  • Include phosphatase inhibitors in lysis buffers when studying phosphorylation

  • Consider crosslinking approaches to capture transient interactions

  • Use membrane fractionation to distinguish cytoplasmic vs. nuclear interaction partners

  • RNase treatment during immunoprecipitation can distinguish RNA-dependent interactions

• Research insights:

  • Lin28A has been shown to interact with RNA processing machinery including TUT4 and TUT7

  • It can modulate signaling pathway components like AKT, ERK, and mTOR

  • The Lin28A-TUT4/7 interaction is critical for let-7 miRNA repression and subsequent effects on pluripotency maintenance

How might Lin28A antibodies be integrated into single-cell analysis workflows?

Emerging single-cell technologies offer exciting applications for Lin28A antibodies:

• Single-cell proteomics applications:

  • Incorporation of Lin28A antibodies into CyTOF/mass cytometry panels

  • Integration with single-cell Western blot technologies

  • Microfluidic antibody-based capture for downstream analysis

• Multi-modal single-cell analysis:

  • CITE-seq approaches combining Lin28A antibody staining with transcriptomics

  • ASAP-seq for simultaneous protein and chromatin accessibility profiling

  • Spatial transcriptomics with antibody staining for contextual Lin28A localization

• Technical considerations:

  • Optimizing antibody concentration is critical for single-cell applications

  • Validation using isotype controls and Lin28A-knockout cells is essential

  • Careful panel design to avoid spectral overlap with other stem cell markers

• Research opportunities:

  • Mapping Lin28A expression heterogeneity within stem cell populations

  • Correlating Lin28A protein levels with let-7 miRNA expression at single-cell resolution

  • Tracking reprogramming dynamics in individual cells through the Lin28A/let-7 axis

What considerations are important when interpreting Lin28A antibody results in comparative studies across species?

Cross-species investigations require careful interpretation:

• Evolutionary conservation aspects:

  • Lin28A is highly conserved across species, with 80-90% sequence similarity among mammals

  • Specific epitopes may show variable conservation, affecting antibody binding

  • Both human and mouse Lin28A proteins have similar molecular weights (approximately 23 kDa calculated, 28 kDa observed)

• Antibody selection for cross-species studies:

  • Choose antibodies validated across your species of interest

  • Several antibodies show confirmed reactivity with human, mouse, and rat Lin28A

  • For novel species, consider western blot validation before immunohistochemistry

• Expression pattern differences:

  • Developmental timing of Lin28A expression may vary between species

  • Tissue-specific expression patterns should be independently validated

  • Functional relevance may differ despite protein conservation

• Technical recommendations:

  • Include species-specific positive controls in each experiment

  • Consider epitope mapping for antibodies used across distant species

  • Be cautious about interpreting negative results in non-validated species